A lot of companies have come forward in order to provide vaccines and to help people in coming over from covid-19. Top 10 covid vaccine companies in 2021
A lot of companies are in the race of making these vaccines. There are more than hundred companies in the list but the those who are providing the best results are as follows
- Merck & Co
- Zydus Cadila
- CNBG (Sinopharm)
- University of Oxford
- Fosun Pharma
- Bharat Biotech
The Hungarian National Institute of Pharmacy and Nutrition has approved the use of vaccines from the company CanSino Biologics.
Convidecia, is a adenovirus-based vector vaccine. It is provided in a single dose regime . Also, It is stored and transported between 2°C to 8°C for its stability
Last year in june this vaccine received a drug Approval in China from the Health Bureau of the Logistics Support Department from the central military commission.
This vaccine received approval for emergency use in India in January while Zimbabwe approved the vaccine earlier this month . It is stable from 2° to 8° C and is transported in ready to use liquid state.
2. Merck & Co.
The Merck & Co has entered into an agreement with J&J’s Janssen Pharmaceuticals company in order to support manufacturing and supply of COVID-19 vaccines.
The efficiency of these vaccines were 72% in US while in 66% Latin America and 57% in South Africa.
This vaccine has been found a little bit less efficient in the B.1.351 variant of COVID-19. Moreover , this one-dose vaccine could be rolled out with more ease and efficiency as compared to other vaccines with two-dose regimens.
3. Zydus Cadila
The company that is currently developing its coronavirus vaccine called ZyCoV-D, claimed that it has received an overwhelming number of orders that are beyond its capacity.
ZydusCadila is a leading Indian pharmaceutical . This company has successfully finished the first two phases of COVID-19 vaccines and is on the way to start the third phase. The phase III trials are likely to be tried over 60 locations and also aims to supply over 100 million COVID vaccines.
Patel said that Cadila is having the capacity to produce over 400,000 doses of vaccines in the first month after it wins the approval to make it in India.
Novavax is a biotechnology company developing next-generation vaccines for serious infectious like the COVID-19
The company has announced that NVX-CoV2373, its protein-based COVID-19 vaccine with the efficacy of 89.3% in the thirt phase. Novavax also announced its successful results of Phase 2 that was conducted in the South Africa
This vaccine is stable at 2°C to 8°C (refrigerated) and is shipped in a ready-to-use liquid formulation for instant use.
The first analysis is based upon 62 cases out of which 56 cases of COVID-19 were observed in the whole group versus 6 cases observed in the NVX-CoV2373 group, resulting in an estimate point of vaccine efficacy as of 89.3%
Novavax has initiated the development of new constructs of vaccines against the emerging strains in January and also expects to select ideal candidates for a its trial
BioNTech is a vaccine creator german company and it has created the Pfizer–BioNTech COVID‑19 vaccine . This vaccine requires two doses for three weeks . It’s clinical trials began by April 2020 only and by November over forty thousand people were provided with its doses.
It provided a efficiency of almost 90% in order to prevent the corona virus
This vaccine showed some of the side effects like fatigue headache and slight pain during its injection into the body.
Moreover these companies Pfizer and BioNTech aims at manufacturing over 2 billion doses in the year 2021 and thus it is followed by various advance orders from different countries such as United Kingdom, United States , European Union, Mexico, Peru , Japan etc.
China National Biotec Group (CNBG) has created the COVID-19 vaccines which claims the efficiency of 79.34% that is at this percentage it provides protection from the corona virus also it meets the requirements as set by WHO for a vaccine to work
The National Medical Products Administration has set the minimum efficiency for the covid vaccines at 50% and the efficiency should not be less than 70%
The CNBG has already started the phase III of vaccination in various countries like the United Arab Emirates, Peru, Japan , Argentina, Egypt , Jordan etc…
The vaccine is initiated in two doses and is tolerable at the ages of 18-59 and 60 and above
CNBG became one of the first companies worldwide to start the vaccination process in humans by testing the first vaccine in April 2020 only .
7.University of Oxford
The vaccines launched by the University of Oxford in collaboration with the AstraZeneca plc has started the third phase of vaccination
The third phase analysis of this vaccine has provided the information that it holds the efficiency of 70.4% .
This vaccine is provided in two regimes the first one shows the efficiency of 90% and the other one has the efficiency of 60%
The vaccine created by the Oxford constitute a weaker virus of cold and infection which is provided with some genetic changes so that it would be nearly impossible for the virus to enter the human body
Moreover there are negligible cases of COVID-19 after taking this vaccine and is providing great results
The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S for use in individuals 18 years of age and older.
During the vaccination process in the first phase each person aging two years to less than 12 years may receive either one of two dose of vaccine also each participant aging six months to less than 2 years may get one of three doses
Any person having any type of allergy from the Moderna COVID-19 Vaccine constituents or with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine should not take this vaccine
Also, in case of a sudden allergic reaction appropriate medical treatment should be given in order to manage allergic reactions , most commonly reported side effects after taking the Moderna vaccine which also lasted for some days were pain at the injection site, tiredness, headache, muscle pain, joint pain, nausea ,vomiting, and fever.
On 16 March 2020, BioNTech and Fosun Pharma had a strategic collaboration to work on the development and of the COVID-19 vaccine products worldwide which was based on BioNTech’s technology platform.
According to the analysis of the third phase Clinical trial, BioNTech’s mRNA-based COVID-19 vaccine met all the basic requirements and thus having the efficiency of 95% in preventing COVID-19 in adults and 94% in populato over 65 years of age.
BioNTech CEO and co-founder Ugur Sahin said: “We would like to thank the Chinese government and National Medical Products Administration for their commitment and trust in our vaccine development efforts to help address this global pandemic threat.
10. Bharat Biotech
Bharat Biotech is a leading pharmaceutical company owning 160 global patents and products of this company help people in over 65 countries to lead life to thier fullest .
The Bharat Biotech announced its phase III of vaccination
The data analysis from 25800 participants have overall claimed that this vaccine is stable as well as tolerable. It has been seen that this vaccine is having 81% efficiency with negligible side effects.
In the second Phase overall 380 participants of 12-65 years were injected with the COVAXIN® and it led to tolerable and safe outcomes .
Bharat biotech has also approached to various countries across the world for the agreement of terms for providing the COVAXIN®.